Related Experiment Video

Updated: Sep 28, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons

I Namura, P Douillet, C J Sun

    European Journal of Pharmacology
    |April 7, 1987
    PubMed

    Insights

    1-Methyl-4-phenylpyridine (MPP+) is a neurotoxin causing cell death in rat brain regions. This oxidative metabolite of MPTP non-selectively damages dopaminergic, noradrenergic, and serotonergic systems.

    Area of Science:

    • Neuroscience
    • Toxicology
    • Pharmacology

    Background:

    • 1-Methyl-4-phenylpyridine (MPP+) is an oxidative metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP).
    • MPTP is known to induce Parkinsonism-like symptoms.

    Purpose of the Study:

    • To investigate the neurotoxic effects of MPP+ on different monoaminergic systems in the rat brain.
    • To determine if MPP+ causes selective or non-selective neuronal damage.

    Main Methods:

    • Stereotaxic intracranial injections of MPP+ into specific rat brain regions (substantia nigra compacta, locus coeruleus, dorsal and median raphe nuclei).
    • Measurement of neurotransmitter levels (dopamine, serotonin, norepinephrine) in terminal areas post-injection.

    Main Results:

    • MPP+ induced local cell death in the injected brain regions.
    • Significant decreases in dopamine, serotonin, and norepinephrine levels were observed.
    • MPP+ demonstrated non-selective neurotoxicity across dopaminergic, noradrenergic, and serotonergic systems.

    Conclusions:

    • MPP+ acts as a non-selective neurotoxin, damaging multiple monoaminergic systems.
    • Selective lesioning of specific monoaminergic systems can be achieved through targeted stereotaxic injection of MPP+ into relevant brain nuclei.

    More Related Videos

    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

    Published on: January 7, 2019

    The 6-hydroxydopamine Rat Model of Parkinson's Disease08:10

    The 6-hydroxydopamine Rat Model of Parkinson's Disease

    Published on: October 27, 2021

    Related Concept Videos

    Drugs Affecting Neurotransmitter Release or Uptake01:21

    Drugs Affecting Neurotransmitter Release or Uptake

    Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
    Parkinson's Disease: Overview01:15

    Parkinson's Disease: Overview

    Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
    Parkinson Disease l: Introduction01:24

    Parkinson Disease l: Introduction

    Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
    Parkinson Disease ll: Pathophysiology01:24

    Parkinson Disease ll: Pathophysiology

    Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...